FRS

Genomics plc and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design

Retrieved on: 
Martedì, Aprile 30, 2024
Genetics, FRS, PRS, Algorithm, Drug development, Drug discovery, GSK, Patient, Human genetics, Pharmaceutical industry

OXFORD, England, April 30, 2024 /PRNewswire/ -- Genomics plc and GSK announced a new collaboration to explore the potential for using polygenic risk scores (PRS) in clinical trials, to improve understanding of disease risk and patient selection, which could support optimisation of trial design. Genomics plc is a global leader in PRS-powered technologies and approaches and has developed extensive genetic databases and algorithms to understand the genetic component of diseases.

Key Points: 
  • OXFORD, England, April 30, 2024 /PRNewswire/ -- Genomics plc and GSK announced a new collaboration to explore the potential for using polygenic risk scores (PRS) in clinical trials, to improve understanding of disease risk and patient selection, which could support optimisation of trial design.
  • Genomics plc is a global leader in PRS-powered technologies and approaches and has developed extensive genetic databases and algorithms to understand the genetic component of diseases.
  • Robert Scott, Vice President of Human Genetics and Genomics at GSK: "Genomics plc is leading in both the development and real-world application of PRS-based approaches, opening up new frontiers in genomic medicine.
  • At GSK, we have demonstrated the opportunity for genetics to guide drug discovery and development; I look forward to working with Genomics plc to further explore the potential for PRS to support clinical trial design."

Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases

Retrieved on: 
Giovedì, Aprile 18, 2024
Health, Fitness & Nutrition, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, GV, Digestion, Capital, ARCH Venture Partners, Reproduction, FRS, Weight loss, Research, Imperial College London, Obesity, Patient, DSM-IV codes, Peptide, Metabolism, Head, Drug development, Fine chemical

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, announced its launch today.

Key Points: 
  • Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, announced its launch today.
  • “Metsera was purpose-built over the last two years to get ahead of the innovation curve in one of the largest and fastest growing markets in the history of biopharma,” said Clive Meanwell, chief executive officer of Metsera.
  • “We have assembled a portfolio of long-acting injectable and oral agents to address multiple next-generation weight loss goals.
  • “Through optimized combinations of injectable and oral peptides, we aim to establish a cycle of continuous and responsive innovation to address a growing worldwide obesity crisis.”

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann

Retrieved on: 
Lunedì, Aprile 8, 2024
Royal, Medicine, FRS, Biochemical Society, Translational research, Wellcome Sanger Institute, Woman, Drug discovery, Trinity College, Royal Society, International, GSK, University, Membrane, Patient, Doctor of Philosophy, EMBO Gold Medal, University College London, Translation, Architecture, Therapy, Immune system, SAB, The Genetics Society, Molecular biology, Pharmaceutical industry

Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.

Key Points: 
  • Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.
  • During this time, she also collaborated with OMass’ co-founder, Professor Dame Carol Robinson, on unraveling the in vivo and in vitro assembly of soluble protein complexes.
  • Ali Jazayeri, Chief Scientific Officer at OMass Therapeutics, commented: “I look forward to working with Sarah.
  • Our previous long-standing collaboration on the assembly of soluble protein complexes demonstrates how her skillset can be complementary to our native mass spectrometry approach and can contribute to further developing our drug discovery platform.”
    Sarah Teichmann, Member of the Scientific Advisory Board of OMass Therapeutics, added: “I am thrilled to be joining OMass Therapeutics’ SAB.

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

Retrieved on: 
Martedì, Marzo 26, 2024
Research, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, FRS, Gene editing, Acute liver failure, New product development, UTHR, Patient, United Therapeutics, Lung, Xenotransplantation, Manuscript, MBBS, Regenerative medicine, PBC, Clinical trial, Therapy, Heart, Creativity, Physiology, Kidney, FACS, FRCS, Liver, Physiological Reviews, Food, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.
  • Beyond xenotransplantation, United Therapeutics has six other organ manufacturing programs in the lung, kidney, and liver using three distinct platforms: regenerative medicine, bio-artificial organs, and 3-D organ printing.
  • United Therapeutics believes that this study will be the first human clinical trial of a manufactured organ.
  • At United Therapeutics, our vision and mission are one.

Global Leaders in Cancer Research and Biotech Join The Mark Foundation for Cancer Research's Scientific Advisory and Industry Advisory Committees

Retrieved on: 
Martedì, Aprile 2, 2024
Molecule, Medicine, Cancer Research UK, FRS, Weill Cornell Medicine, Francis Crick Institute, B cell, Patient, Investment, Children's National Hospital, Therapy, Research, Biotechnology, Genentech, Dana–Farber Cancer Institute, Committee, Trial of the century, University, University College Hospital, Metastasis, Multiple sclerosis, Drug discovery, MBBS, Chairperson, MD, University College London, Senior, FRCP, University of California, Berkeley, Hospital, Nationwide Children's Hospital, Marker beacon, Diagnosis, Lung cancer, Ludwig Cancer Research, University of Pennsylvania, Doctor of Philosophy, BTK, GV (company), Celera Corporation, Pharmaceutical industry

NEW YORK, April 2, 2024 /PRNewswire/ -- The Mark Foundation for Cancer Research, a leading nonprofit dedicated to advancing research that transforms the prevention, diagnosis, and treatment of cancer, proudly announces the appointment of new members to its Scientific Advisory and Industry Advisory Committees.

Key Points: 
  • The committee assists the foundation in reviewing its scientific goals and grant applications, as well as providing strategic advice and support for its research programs and investments.
  • "The outstanding researchers on our advisory committees provide invaluable guidance and insight to help steer its programs toward success and impact."
  • "The Mark Foundation's funding of high-risk, high-impact research is essential in the quest to achieve real breakthroughs in cancer research," said Johanna Joyce, PhD.
  • "I am honored to join the Scientific Advisory Committee, to support the next generations of scientists and projects that will revolutionize treatments for patients."

Oracle Helps Organizations Effectively Manage Sustainability Initiatives

Retrieved on: 
Giovedì, Marzo 14, 2024
Cloud, Narrative, Create, Automation, FRS, Organization, Biophysical environment, International, Connect, AI, Anomaly, GRI, EPM, Sustainability, Product management, Machine learning

LONDON, March 14, 2024 /PRNewswire/ --  Oracle CloudWorld -- Oracle today announced Oracle Cloud EPM for Sustainability, a new solution in Oracle Fusion Cloud Enterprise Performance Management (EPM) that helps organizations efficiently measure and effectively manage sustainability initiatives. The new solution will help business leaders gain the insights they need to make progress on sustainability goals by connecting data, plans, and targets across their organization, and by modeling multiple scenarios to optimize outcomes.

Key Points: 
  • New sustainability capabilities in Oracle Cloud EPM help business leaders efficiently plan, track, and report on initiatives and comply with new reporting standards
    LONDON, March 14, 2024 /PRNewswire/ --  Oracle CloudWorld -- Oracle today announced Oracle Cloud EPM for Sustainability , a new solution in Oracle Fusion Cloud Enterprise Performance Management (EPM) that helps organizations efficiently measure and effectively manage sustainability initiatives.
  • "With Oracle Cloud EPM for Sustainability, our customers can leverage a trusted solution that embeds AI and other advanced technologies to help improve efficiency, deliver insights, promote compliance, and effectively manage their progress on sustainability initiatives."
  • Oracle Cloud EPM for Sustainability helps organizations accelerate their sustainability efforts.
  • With an enhanced understanding of the risks and opportunities for each initiative, organizations can make smarter decisions about sustainability initiatives and drive greater impact.

Genomics plc publishes clinical trial results demonstrating successful integration and clinical utility of integrated risk scores combining polygenic and clinical risk of cardiovascular disease in NHS primary care

Retrieved on: 
Mercoledì, Gennaio 31, 2024
NHS health check, GP, CVD, Cholesterol, Genetics, Knowledge, Family, IRT, Heart, FRS, Cardiovascular disease, Clinical trial, Risk assessment, BMI, Patient, Ageing, Friends, Durham University, NHS, European Journal, Risk, PRS, National Health Service, Blood pressure, Absolute risk

The HEART Study is the world's first clinical trial investigating the use of genomic 'polygenic risk score (PRS) testing' to support the prevention of cardiovascular disease (CVD) in National Health Service (NHS) clinical practice.

Key Points: 
  • The HEART Study is the world's first clinical trial investigating the use of genomic 'polygenic risk score (PRS) testing' to support the prevention of cardiovascular disease (CVD) in National Health Service (NHS) clinical practice.
  • It was designed to evaluate an integrated risk tool (IRT) that combines genetic risk in the form of a polygenic risk score or PRS, with QRISK, a prediction algorithm for CVD.
  • For people aged 45-64, genetics accounts for 40% as much risk as all the non-genetic risk factors combined in QRISK.
  • We hope that it will also encourage similar studies incorporating genetics into clinical risk prediction for other common diseases."

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

Retrieved on: 
Martedì, Gennaio 9, 2024
Bile, Woman, Hyperemesis gravidarum, Research, Biology, Hospital, Weight loss, MSS, FRS, Hepatology, University, ILT3, Liver disease, FGF19, GFRAL, LAIR1, Liver, Doctor of Philosophy, NASH, CRC, Pembrolizumab, Trial of the century, Neoplasm, NGM, SAN, PRS, Public health, Genetic epidemiology, Preterm birth, Vomiting, Cirrhosis, DCR, Dehydration, AASLD, Immunotherapy, Place of birth, Medicine, Pregnancy, Pre-eclampsia, Therapy, ELF, Patient, Bile acid malabsorption, Fibrosis, Nausea, Alkaline phosphatase, PSC, Gastrointestinal disease, CRN, IBS-D, Malnutrition, FDA, Biomarker, Pharmaceutical industry

NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.

Key Points: 
  • NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.
  • Recent landmark genetic research confirmed the link between this rare, devastating condition experienced during pregnancy to higher levels of GDF15.
  • Given our deep expertise in GDF15 biology, we believe we are well positioned to potentially pursue this indication for NGM120.
  • NGM Bio previously reported data from a randomized, double-blind, placebo-controlled Phase 2 study of aldafermin for the treatment of PSC.

DnaNudge secures FDA approval to deploy a Multiplex PCR platform for diagnosing four-in-one respiratory pathogens in Ghana

Retrieved on: 
Giovedì, Dicembre 14, 2023
Health, FDA, Medical Devices, Infectious Diseases, Genetics, COVID-19, Biotechnology, Diabetic foot infection, FRS, DnaNudge, Vertically transmitted infection, Research, Urinary tract infection, DNA, RSV, Diabetic foot, Respiratory syncytial virus, Laureate, The Lancet, Clinical trial, Genomics, PCR, University, Medicine, Infection, Biomedicine, City, Medical research, University of Ghana, Imperial College London, RT, Partnership, RNA, Doctor of Philosophy, Quad, AI, SARS, Biomedical engineering, Life, TB, COVID, Vaccine, Medical device, Pharmaceutical industry

The lab-free, highly multiplexed sample-to-result test offers the capabilities of lab-based PCR diagnostics.

Key Points: 
  • The lab-free, highly multiplexed sample-to-result test offers the capabilities of lab-based PCR diagnostics.
  • Unlike the majority of other nucleic acid point-of-care tests based on isothermal amplification methods, the DnaNudge technology uses gold standard RT-PCR.
  • Testing samples can be collected via nasopharyngeal, nasal only or combined nose and throat swabs.
  • The unique lab-free nature of the DnaNudge system means that the test is ideal for use by healthcare professionals in any setting, including urban and rural environments.

Recognizing and Celebrating Outstanding Contributions to the Canadian Cancer Research Community

Retrieved on: 
Lunedì, Novembre 6, 2023
Women of Outstanding Achievement Photographic Exhibition, FRSC, ISCB Senior Scientist Award, Order of Ontario, FCAN, Medical research, Myeloma Canada, Molecular biology, Multiple myeloma, FRS, Genetics, Jewish General Hospital, Psycho-oncology, RN, Conference, Organization, Federation, Doctor of Philosophy, FRCPC, Doctor of Science, University of Hong Kong, Research, Toronto Metropolitan University, Patient, Senior, McGill University, Princess Margaret Cancer Centre, Professor, University of Toronto, Immune system, Canadian Partnership Against Cancer, University, OC, FCAHS, Palliative care, Distinguished Service to Music Medal, CCRA, Toronto, Breast cancer, University Health Network, University of Manitoba, Ovarian Cancer Research Alliance, Pharmaceutical industry, Nursing, Management, MD, Pharmacology, Cancer

TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.

Key Points: 
  • TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.
  • Awardees will be honoured at the Canadian Cancer Research Conference, which is taking place in Halifax from November 12 to 14.
  • Initiated in 2011, the CCRA Awards acknowledge and celebrate the contributions of individuals who have had a remarkable impact on cancer research and the cancer research community, as well as those who have shown exceptional leadership in patient involvement in cancer research.
  • The Canadian Cancer Research Alliance (CCRA) is an alliance of organizations that collectively fund most of the cancer research conducted in Canada – research that will lead to better ways to prevent, diagnose, and treat cancer, and improve patient and survivor outcomes.